- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06029478
Understanding Engagement Trends in Chondrosarcoma Clinical Trials
Understanding Engagement Trends in Chondrosarcoma Clinical Trials: Investigating Participation Patterns Among Chondrosarcoma Patients
Taking part in medical research usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.
This study will admit a wide range of data on the clinical trial experience of chondrosarcoma patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.
It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future chondrosarcoma patients.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Michael B Gill
- Phone Number: 415-900-4227
- Email: bask@withpower.com
Study Locations
-
-
California
-
San Francisco, California, United States, 94107
- Power Life Sciences
-
Contact:
- Michael B Gill
- Phone Number: 415-900-4227
- Email: https://www.withpower.com/contact-us@withpower.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged ≥ 18 years old
- Able to comprehend the investigational nature of the protocol and provide informed consent
- Diagnosis of chondrosarcoma
Exclusion Criteria:
- No diagnosis of chondrosarcoma confirmed
- Inability to perform regular electronic reporting
- Patient does not understand, sign, and return consent form
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of chondrosarcoma patients who decide to enroll in a clinical trial
Time Frame: 3 months
|
3 months
|
|
Rate of chondrosarcoma patients who remain in clinical trial to trial completion
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Publications and helpful links
General Publications
- Speetjens FM, de Jong Y, Gelderblom H, Bovee JV. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment. Curr Opin Oncol. 2016 Jul;28(4):314-22. doi: 10.1097/CCO.0000000000000300.
- Beena D, Kattoor J, Mathews A, P Nair S, M V, T P, N G. Mesenchymal Chondrosarcoma-A Retrospective study. Gulf J Oncolog. 2021 Jan;1(35):54-58.
- Thompson LD, Gannon FH. Chondrosarcoma of the larynx: a clinicopathologic study of 111 cases with a review of the literature. Am J Surg Pathol. 2002 Jul;26(7):836-51. doi: 10.1097/00000478-200207000-00002.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 84518615
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chondrosarcoma
-
National Cancer Institute (NCI)Active, not recruitingMesenchymal Chondrosarcoma | Dedifferentiated Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Clear Cell Chondrosarcoma | Locally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Primary Central ChondrosarcomaFrance
-
Leiden University Medical CenterCompletedMyxoid Liposarcoma | Mesenchymal Chondrosarcoma | Dedifferentiated Chondrosarcoma | Conventional ChondrosarcomaSpain, Netherlands
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Primary Central Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Locally Advanced Unresectable Primary Central ChondrosarcomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingDedifferentiated Chondrosarcoma | Central Chondrosarcoma, Grade 2 | Central Chondrosarcoma, Grade 3 | Metastatic Clear Cell Sarcoma of Soft Tissue | Metastatic Primary Central Chondrosarcoma | Unresectable Primary Central ChondrosarcomaUnited States, Canada
-
Italian Sarcoma GroupPharmaMarRecruitingMesenchymal ChondrosarcomaItaly
-
Istituto Ortopedico RizzoliIstituto Nazionale Tumori IRCCS - Fondazione G. Pascale; Azienda Ospedaliera... and other collaboratorsActive, not recruiting
-
Medical University of GrazNot yet recruiting
-
Istituto Ortopedico RizzoliCompleted
-
Istituto Ortopedico RizzoliCompleted
-
George Clinical Pty LtdGlaxoSmithKlineCompletedChondrosarcoma | Metastatic ChondrosarcomaUnited States, United Kingdom